Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06030674

Measuring Environmental Tobacco and Cannabis: Pollutants and Exposures

This is an unblinded pilot study of an environmental exposure to secondhand cannabis smoke in one group of healthy nonsmokers.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

21 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Zuckerberg San Francisco General Hospital

San Francisco, California, 94110, United States

Location status: Recruiting

Location contact

Abel Huang

CONTACT

[email protected]

Suzyann Schick, PhD

PRINCIPAL_INVESTIGATOR

About this study

The goal is to gather accurate information on uptake of smoke toxicants from cannabis exposures in the real world. The investigators will be taking healthy nonsmokers to public places where people are consuming cannabis and measuring their uptake of cannabinoids.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

-

Adult nonsmokers, aged 21-50, who:

  • Are healthy on the basis of medical history
  • Have systolic blood pressure <150
  • Have diastolic blood pressure <100
  • Have BMI between 18.1 and 34.9
  • Able to perform moderate exercise,
  • Are not exposed to tobacco or cannabis SHS in their daily lives. (Nonsmoking status and low SHS exposure are determined by self-report on the screening questionnaire, salivary cotinine < 10 ng/ml and THC < 50 ng/m and exhaled CO2 below 4 ppm)

Exclusion criteria

  • Current use of cannabis products, including CBD and edible THC products
  • Regular exposure to secondhand tobacco or cannabis smoke
  • Positive SARS-CoV-2 antibody test
  • Age 18 < or > 50
  • Physician diagnosis of asthma, heart disease, hypertension, thyroid disease, diabetes, renal or liver impairment or glaucoma.
  • Unstable psychiatric condition (such as current major depression, history of schizophrenia or bipolar disorder) or current use of more than two psychiatric medications
  • Systolic blood pressure > 150
  • Diastolic blood pressure > 100
  • Pregnancy or breastfeeding (by urine hCG and/or history)
  • Alcohol or illicit drug dependence within the past 5 years
  • BMI > 35 and < 18
  • Current illicit drug use (by history or urine test)
  • More than 1 pack year smoking history
  • Ever a daily marijuana smoker
  • Smoked anything within the last 2 months
  • Occupational exposure to smoke, dusts OR fumes
  • Concurrent participation in another clinical trial
  • Unable to communicate in English
  • No social security number

Treatment and study plan

Secondhand cannabis emissions/smoke exposure

Other

This is an environmental exposure performed in public places where people are consuming cannabis.

Primary outcomes

  1. Change in the concentration of urinary cannabinoid metabolites in health nonsmokers exposed to cannabis smoke and emissions

    Time frame: Baseline (before exposure) and the morning after exposure, up to 22 hours.

    The concentration of 11-Nor-9-carboxy-THC will be measured in urine with LC/MS-MS. The LOQ for this assay is 15 pg/ml. Anticipated changes in concentration are from BLOQ to 0.5-20 ng/ml. The duration of the exposures will depend on the event or venue at which exposures occur, ranging from 30 minutes to 4 hours. The investigators will compare the concentration of 11-Nor-9-carboxy-THC in participants' urine before exposure to concentrations in the first void of the morning after the day of exposure.

Study contacts

Contact information is provided by the study sponsor or research team.

Abel Huang, BS

CONTACT

[email protected]

415-514-9011

Suzaynn F Schick, Phd

CONTACT

[email protected]

4155143535

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Registry information

Acronym: CAN03

Important dates

Study start
2023
Primary completion
2027
Study completion
2027
First posted
Sep 11, 2023
Registry last updated
Jun 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.